within Pharmacolibrary.Drugs.ATC.C;

model C10BX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.21666666666666667,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed-dose combination of rosuvastatin, a HMG-CoA reductase inhibitor (statin), and valsartan, an angiotensin II receptor blocker (ARB). It is proposed for treatment of coexisting hypercholesterolemia and hypertension in adults. This combination is not widely approved as a fixed single formulation but may be used in clinical trials or off-label co-administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical healthy adult population, since no fixed-dose combination studies or published PK models exist for this specific combination product. Values estimated from published PK parameters for individual drugs (rosuvastatin and valsartan) and standard modeling assumptions.</p><h4>References</h4><ol><li><p>Mochizuki, T, et al., &amp; Kusuhara, H (2022). Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. <i>Clinical and translational science</i> 15(6) 1519–1531. DOI:<a href=&quot;https://doi.org/10.1111/cts.13272&quot;>10.1111/cts.13272</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35421902/&quot;>https://pubmed.ncbi.nlm.nih.gov/35421902</a></p></li><li><p>Hooper, L, et al., &amp; Pai, MP (2025). GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. <i>Pharmacotherapy</i> 45(4) 211–219. DOI:<a href=&quot;https://doi.org/10.1002/phar.70007&quot;>10.1002/phar.70007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39989027/&quot;>https://pubmed.ncbi.nlm.nih.gov/39989027</a></p></li><li><p>Mochizuki, T, et al., &amp; Kusuhara, H (2022). Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. <i>Clinical pharmacology and therapeutics</i> 111(6) 1315–1323. DOI:<a href=&quot;https://doi.org/10.1002/cpt.2584&quot;>10.1002/cpt.2584</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35292967/&quot;>https://pubmed.ncbi.nlm.nih.gov/35292967</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10BX10;
